These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 31702883)

  • 21. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    Kowdley KV; Bowlus CL; Levy C; Akarca US; Alvares-da-Silva MR; Andreone P; Arrese M; Corpechot C; Francque SM; Heneghan MA; Invernizzi P; Jones D; Kruger FC; Lawitz E; Mayo MJ; Shiffman ML; Swain MG; Valera JM; Vargas V; Vierling JM; Villamil A; Addy C; Dietrich J; Germain JM; Mazain S; Rafailovic D; Taddé B; Miller B; Shu J; Zein CO; Schattenberg JM; ;
    N Engl J Med; 2024 Feb; 390(9):795-805. PubMed ID: 37962077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of difelikefalin in the treatment of hemodialysis patients with pruritus: A meta-analysis and systematic review.
    Xue G; Yuan H; Fan D; Yang Y; Ma C; Liu J; Liao R
    Clin Nephrol; 2024 Apr; 101(4):155-163. PubMed ID: 38294219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease.
    Lipman ZM; Yosipovitch G
    Expert Opin Pharmacother; 2021 Apr; 22(5):549-555. PubMed ID: 33190563
    [No Abstract]   [Full Text] [Related]  

  • 24. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus.
    Mathur VS; Kumar J; Crawford PW; Hait H; Sciascia T;
    Am J Nephrol; 2017; 46(6):450-458. PubMed ID: 29253847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous difelikefalin for the treatment of hemodialysis pruritus.
    Mahmoud RH; Mahmoud O; Yosipovitch G
    Expert Rev Clin Immunol; 2024; 20(1):31-37. PubMed ID: 37847514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
    Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial.
    von Maltzahn R; Mayo MJ; Smith HT; Thompson A; Das S; de Souza AR; Lisi E; Levy C; McLaughlin MM; Jones D
    J Patient Rep Outcomes; 2024 Jun; 8(1):60. PubMed ID: 38862718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
    Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
    EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the physical dependence potential of difelikefalin: Randomized placebo-controlled study in patients receiving hemodialysis.
    Spencer RH; Munera C; Shram MJ; Menzaghi F
    Clin Transl Sci; 2023 Sep; 16(9):1559-1568. PubMed ID: 37128642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study.
    Kinugasa E; Igawa K; Shimada H; Kondo M; Funakoshi S; Imada N; Itami N; Fukazawa N; Takubo R; Kawata Y; Murota H
    Clin Exp Nephrol; 2021 Aug; 25(8):875-884. PubMed ID: 33754202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis.
    Thokala P; Hnynn Si PE; Hernandez Alava M; Sasso A; Schaufler T; Soro M; Fotheringham J
    Pharmacoeconomics; 2023 Apr; 41(4):457-466. PubMed ID: 36735201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies.
    Wikström B; Gellert R; Ladefoged SD; Danda Y; Akai M; Ide K; Ogasawara M; Kawashima Y; Ueno K; Mori A; Ueno Y
    J Am Soc Nephrol; 2005 Dec; 16(12):3742-7. PubMed ID: 16251241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Difelikefalin: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1937-1944. PubMed ID: 34674115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
    Hirschfield GM; Bowlus CL; Mayo MJ; Kremer AE; Vierling JM; Kowdley KV; Levy C; Villamil A; Ladrón de Guevara Cetina AL; Janczewska E; Zigmond E; Jeong SH; Yilmaz Y; Kallis Y; Corpechot C; Buggisch P; Invernizzi P; Londoño Hurtado MC; Bergheanu S; Yang K; Choi YJ; Crittenden DB; McWherter CA;
    N Engl J Med; 2024 Feb; 390(9):783-794. PubMed ID: 38381664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.
    Yokozeki H; Murota H; Matsumura T; Komazaki H;
    Br J Dermatol; 2024 Jul; 191(2):200-208. PubMed ID: 38629497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
    Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
    N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation.
    Ständer S; Zeidler C; Pereira M; Szepietowski JC; McLeod L; Qin S; Williams N; Sciascia T; Augustin M
    J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):573-581. PubMed ID: 34908192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double-blind, placebo-controlled trial.
    Viscusi ER; Torjman MC; Munera CL; Stauffer JW; Setnik BS; Bagal SN
    Clin Transl Sci; 2021 Sep; 14(5):1886-1893. PubMed ID: 33982405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transformation of 5-D itch scale and numerical rating scale in chronic hemodialysis patients.
    Lai JW; Chen HC; Chou CY; Yen HR; Li TC; Sun MF; Chang HH; Huang CC; Tsai FJ; Tschen J; Chang CT
    BMC Nephrol; 2017 Feb; 18(1):56. PubMed ID: 28178931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis.
    Rastogi A; Fishbane S; Lerma E
    Expert Rev Clin Pharmacol; 2023 May; 16(5):387-400. PubMed ID: 37010031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.